Over 12,000 women between the ages of 15 and 26 years were randomised to receive three doses of either Gardasil or placebo. The primary composite endpoint was cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma in situ, or cervical cancer related to HPV-16 or HPV-18.
Vaccine efficacy for the prevention of the primary composite endpoint was 98 per cent.
The full paper can be found on the New England Journal of Medicine website.
What do you think? Comment below or email us at email@example.com